Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
188.51
272.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Common Shares Outstanding
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Common Shares Outstanding
¥603.3m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Common Shares Outstanding
¥5.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Common Shares Outstanding
¥6.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Common Shares Outstanding
¥1.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
6%
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Common Shares Outstanding
¥1.4B
|
CAGR 3-Years
37%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Common Shares Outstanding
¥401m
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Glance View
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. is a beacon of traditional Chinese medicine, rooted in a legacy that dates back over four decades. Specializing in the production of proprietary herbal medicines, particularly its flagship product, Pientzehuang, the company expertly marries ancient healing practices with modern pharmaceutical standards. The company's commitment to quality and innovation is evident in its meticulous sourcing of raw materials and rigorous R&D efforts, positioning it as a leader in the herbal medicine sector. Zhangzhou's extensive distribution network spans both domestic and international markets, enhancing its brand recognition and further entrenching its products in the hearts and homes of patients seeking natural remedies. As the global demand for alternative healthcare solutions continues to rise, Zhangzhou Pientzehuang stands at the forefront of this burgeoning market. The company's unwavering focus on expanding its product line and leveraging e-commerce platforms provides lucrative opportunities for growth. Additionally, its strategic partnerships with healthcare institutions and researchers underscore its credibility and commitment to advancing healthcare. For investors, Zhangzhou Pientzehuang represents not merely an investment in a company, but a stake in the revival and global acceptance of traditional Chinese medicine, a field that resonates with the increasing emphasis on holistic health and wellness. With a robust business model and a future poised for expansion, the company stands as an attractive candidate for those looking to invest in the convergence of tradition and modern healthcare innovation.
See Also
What is Zhangzhou Pientzehuang Pharmaceutical Co Ltd's Common Shares Outstanding?
Common Shares Outstanding
603.3m
CNY
Based on the financial report for Jun 30, 2024, Zhangzhou Pientzehuang Pharmaceutical Co Ltd's Common Shares Outstanding amounts to 603.3m CNY.
What is Zhangzhou Pientzehuang Pharmaceutical Co Ltd's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
0%
Over the last year, the Common Shares Outstanding growth was 0%.
You don't have any saved screeners yet
